^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    bortezomib (Proteasome inhibitor) +
    Synribo (omacetaxine mepesuccinate) (Apoptosis stimulant, MCL1 inhibitor, MYC inhibitor, Protein synthesis inhibitor, G1-S-specific cyclin-D1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL

    Published date:
    05/11/2023
    Excerpt:
    We enrolled 21 patients with R/R AML (median age, 42 [range, 30–62] years), who received BHA reinduction therapy (bortezomib, 1.3 mg/m2/day on days 1 and 4; homoharringtonine, 4 mg/m2/day and cytarabine, 1.5 g/m2/day for 5 days)....Overall response and CR/CRi rates in FLT3-mutated R/R-AML reached 66.7% (P=0.03 vs that in FLT3 wild-type R/R AML).